KMT2A and breast cancer: Dual PI3K/MLL inhibition selectively reduced the viability of PIK3CA-mutated, HR+ breast cancer cell lines, as the viability of both the PI3K pathway wildtype, HR+ breast cancer cell line HCC1500 and the normal breast cell line MCF10A remained unchanged (Supplementary Fig. S4B and S4C).